Please assess the completion status of the following clinical trial:

Trial Title: PROlonGed ExpoSure Sertraline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is an Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) combat veteran with chronic posttraumatic stress disorder (PTSD) or significant PTSD symptoms (Clinician Administered Posttraumatic Stress Disorder Scale \[CAPS\] \>= 50) of at least 3 months duration~Exclusion Criteria:~* Current, imminent risk of suicide (as indicated on C-SSRS)~* Active psychosis~* Alcohol or substance dependence in the past 8 weeks~* Unable to attend regular appointments~* Prior intolerance or failure of adequate trial of prolonged exposure (PE) or sertraline (SERT) (defined as at least 2 months of SERT at least 100mg/day)~* Medical illness likely to result in hospitalization or for which treatments are contraindicated (based on lab results, medical history and physical exam)~* Serious cognitive impairment (as evidenced by cognitive impairment felt likely to interfere with the ability to participate meaningfully in the study)~* Concurrent antidepressants or antipsychotics~* Pregnant females

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sertraline + enhanced medication management (SERT/EMM) (Type: ACTIVE_COMPARATOR): 24 weeks of sertraline + enhanced medication management
- Prolonged Exposure + sertraline (PE/SERT) (Type: ACTIVE_COMPARATOR): Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
- Prolonged Exposure + placebo (PE/PLB) (Type: ACTIVE_COMPARATOR): Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).